Lipocine Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
17.5%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$1.55next fiscal year
Monitoring Framework
Key Performance Indicators
Unrestricted Cash, Cash Equivalents, and Marketable Investment Securities Quarterly24.7MTarget: Sufficient to fund operations and clinical trials into 2027
Quarterly Net Loss Quarterly-3.7MTarget: Minimize cash burn through strategic partnerships
TLANDO Royalty Revenue Quarterly119KTarget: Maximize commercialization royalties via global partners
Watch Items
- LPCN 1154 (Oral Brexanolone) Regulatory Path for Postpartum DepressionTrigger: FDA guidance meeting outcome regarding the exclusion of the anomalous clinical siteAction: Determine if a new validation trial is required or if the FDA will accept the post-hoc subgroup analysis for NDA submission
- LPCN 1144 (Oral Treatment for MASH) Partnering ProgressTrigger: Execution of a licensing or co-development agreementAction: Secure non-dilutive funding and milestone-based development support
- LPCN 1148 (Management of Decompensated Cirrhosis) Phase 2 OLE and PartneringTrigger: Partnering discussions and regulatory feedback on Phase 2 dataAction: Establish a strategic partnership to advance LPCN 1148 into Phase 3 trials
Research as of 20 Jun 2026